Page last updated: 2024-10-27
gentamicin and Cockayne-Touraine Disease
gentamicin has been researched along with Cockayne-Touraine Disease in 1 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease caused by mutations in the gene encoding type VII collagen, the major component of anchoring fibrils (AF)." | 2.84 | Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. ( Chen, M; Cogan, J; Hou, Y; Keene, D; Lyu, C; Marinkovich, MP; Woodley, DT, 2017) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Woodley, DT | 1 |
| Cogan, J | 1 |
| Hou, Y | 1 |
| Lyu, C | 1 |
| Marinkovich, MP | 1 |
| Keene, D | 1 |
| Chen, M | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| [NCT02698735] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2016-02-25 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Participants With Anchoring Fibrils as Assessed by Immuno-electron Microscopy
The expression of anchoring fibril structures at the patients' dermal-epidermal junction was assessed by immuno-electron microscopy (IEM) using an antibody specific to type VII collagen. The IEM expression of anchoring fibrils was assessed before treatment and at one and three months after treatment. At each assessment time point, anchoring fibrils were compared with normal human skin. Baseline pre-treatment and one and three month post-treatment sites were compared for the presence of anchoring fibrils after gentamicin treatment (or increase if anchoring fibrils were detected at baseline in patients). Comparisons were also made between placebo-treated and gentamicin-treated sites. (NCT02698735)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|
| Topical Gentamicin Ointment | 3 |
| Topical Placebo Ointment | 0 |
| Intradermal Gentamicin Injection | 3 |
| Intradermal Placebo Injection | 0 |
Restoration of Full-length Type VII Collagen as Assessed by Immunofluorescence.
The expression of type VII collagen at the patients' dermal-epidermal junction was assessed by immunofluorescence (IF) using an antibody specific to type VII collagen. The expression was semi-quantitated using NIH Image J software. The IF expression of type VII collagen was assessed before treatment and at one and three months after treatment for each patient. All treated and untreated sites for all patients were also analyzed to determine statistical significance of treatment versus placebo for topical and intradermal administrations. At each assessment time point, type VII collagen expression was also measured in normal human skin. The expression of type VII collagen was then expressed as a percentage of the type VII collagen expressed in normal human skin. (NCT02698735)
Timeframe: 3 months
| Intervention | Fluorescence Intensity (MFI) for C7 (Mean) |
|---|
| Topical Gentamicin Ointment | 5 |
| Topical Placebo Ointment | 5 |
| Intradermal Gentamicin Injection | 4 |
| Intradermal Placebo Injection | 4 |
Trials
1 trial available for gentamicin and Cockayne-Touraine Disease